Anthony Fauci

Anthony Stephen Fauci is an American physician-scientist and immunologist who directed the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), from 1984 to 2022. He advised seven United States presidents on infectious diseases and served as chief medical adviser to President Joe Biden before leaving federal service in December 2022. His career combined clinical investigation, biomedical research administration, and public health policy. (niaid.nih.gov)

Fauci’s research addressed immune regulation, immune-mediated diseases, and the mechanisms of HIV/AIDS. His subsequent work included collaboration with AIDS advocates, participation in the development of the President’s Emergency Plan for AIDS Relief (PEPFAR), and leadership of NIAID during successive infectious-disease emergencies, including the COVID-19 pandemic. These activities connected laboratory and clinical research with patient participation, international health programs, and communication between scientists and government. (history.nih.gov)

After leaving NIH, Fauci joined Georgetown University in July 2023 as a Distinguished University Professor, with appointments in medicine and public policy. His later activities include medical education, mentoring, public lectures, and the publication of his 2024 memoir, <i>On Call: A Doctor’s Journey in Public Service</i>. (georgetown.edu)

Education and Entry into Medical Research

Anthony Fauci was born in December 1940 and grew up in Brooklyn, New York City, where his family owned a neighborhood pharmacy. His father, Stephen, was a pharmacist. In later recollections, Fauci described delivering prescriptions by bicycle in Bensonhurst and Dyker Heights and encountering illness in the ordinary circumstances of patients’ homes. He identified those deliveries as an early influence on his interest in medicine. This account of the pharmacy’s formative significance is autobiographical: it records how Fauci subsequently interpreted his childhood experience, rather than establishing a single cause for his career choice. (history.nih.gov)

Fauci attended Regis High School, a Jesuit school in Manhattan, before entering the College of the Holy Cross in Worcester, Massachusetts, in 1958. He graduated in 1962; the college’s yearbook records his degree as an A.B. in premedical studies. In his March 7, 1989, oral-history interview, he described a curriculum combining Greek, Latin, French, and 32 credits of philosophy with the science courses required for medical-school admission. He credited this humanistic education with teaching disciplined reasoning and concise scientific communication. In remarks reported by Georgetown University in February 2024, he also identified the Jesuit emphasis on service as an influence on his decision to become a physician-scientist. These explanations represent his retrospective assessment of his education. (libguides.holycross.edu)

He entered Cornell University Medical College in 1962 and received his M.D. in 1966, graduating first in his class. From 1966 to 1968, he undertook internship and residency training in internal medicine at New York Hospital–Cornell Medical Center. His initial ambition remained principally clinical: in later interviews, he recalled seeking to emulate physicians whose expertise lay in diagnosis and patient care. The transition toward research nevertheless occurred within medical training rather than as a departure from it; he had already developed an interest in immunology and participated in student research at Cornell. (pmc.ncbi.nlm.nih.gov)

The Vietnam-era physician draft shaped his next appointment. Recalling the recruitment process in a July 17, 2001, NIH oral history, Fauci explained that medical students were informed of their service obligations and the available military and Public Health Service options. He selected the NIH route, interviewed at several institutes, and chose the National Institute of Allergy and Infectious Diseases (NIAID), where Sheldon Wolff selected him. In 1968, he joined the National Institutes of Health as a clinical associate in NIAID’s Laboratory of Clinical Investigation. The appointment combined service through the Public Health Service with specialized research training. (history.nih.gov)

Wolff’s laboratory provided a setting in which clinical observation and laboratory investigation could be pursued together. Working with John Johnson and learning from investigators in neighboring laboratories, Fauci acquired experimental immunology techniques while developing an interest in regulation of the human immune system. In his later account, Wolff’s willingness to support work beyond the laboratory’s existing specialties was important to that development. Fauci returned to Cornell as chief resident in 1971–1972, with Wolff offering him a laboratory position afterward. This arrangement allowed him to complete further clinical training before returning to NIH to establish his research group. (history.nih.gov)

Immune Regulation and Immune-Mediated Disease

Fauci’s early research at the National Institute of Allergy and Infectious Diseases developed along two connected lines: investigating how the human immune system is regulated, and studying diseases in which immune activity damages tissues. In his March 1989 oral-history interview, he described learning cellular immunology while working in Sheldon M. Wolff’s Laboratory of Clinical Investigation, initially under immunochemist John S. Johnson. Laboratory studies of immune regulation proceeded alongside clinical investigations of systemic inflammatory disorders. Wolff’s patients with prolonged, unexplained fevers included people with vasculitic diseases, providing a clinical setting for investigating both disease mechanisms and immunosuppressive treatment. (history.nih.gov)

A principal focus was granulomatosis with polyangiitis, then called Wegener’s granulomatosis. Fauci and Wolff developed a systematic protocol to investigate cyclophosphamide, a cytotoxic drug previously developed for cancer treatment. Their rationale drew partly on animal experiments suggesting that lower doses could suppress immune activity without the profound bone-marrow suppression associated with intensive anticancer regimens. On December 30, 1971, Fauci, Wolff, and Johnson published “Effect of cyclophosphamide upon the immune response in Wegener’s granulomatosis” in the New England Journal of Medicine. The paper connected investigation of the drug’s immunological effects with its clinical use; Fauci and Wolff subsequently published a study of eighteen patients and a literature review in Medicine in November 1973. (history.nih.gov)

The clinical program subsequently examined cyclophosphamide together with the corticosteroid prednisone. In January 1983, Fauci, Barton F. Haynes, Phyllis Katz, and Wolff reported the NIH team’s experience with 85 patients studied over a 21-year period. Their historical protocol used daily cyclophosphamide and prednisone, followed by conversion of prednisone to alternate-day administration. Complete remission was reported in 79 patients, or 93%; the mean remission duration among living patients was 48.2 months. Twenty-three patients had stopped all therapy and had remained without treatment for an average of 35.3 months. These were results from a longitudinal clinical series, not a randomized comparison, and the reported endpoint was remission rather than proof of permanent cure. (pubmed.ncbi.nlm.nih.gov)

Parallel laboratory investigations examined what immunosuppressive drugs did to circulating immune cells. In a January 1974 Journal of Clinical Investigation paper, Fauci and David C. Dale studied healthy subjects after a single intravenous dose of hydrocortisone. Circulating lymphocyte and monocyte counts fell markedly within four to six hours and returned to normal by 24 hours. The investigators also measured changes in lymphocyte subsets and their responses to laboratory stimulation. They interpreted the transient changes as most consistent with redistribution of cells from blood into other body compartments, rather than simply destruction of the cells. This distinguished a reduced blood-cell count from a uniform loss of immune function throughout the body. (pubmed.ncbi.nlm.nih.gov)

Treatment safety was itself a subject of investigation. Dale, Fauci, and Wolff published studies of cyclophosphamide, white-cell kinetics, and susceptibility to infection in 1973, and of alternate-day prednisone in 1974. Fauci and Dale’s 1975 study of patients receiving alternate-day prednisone found transient decreases in circulating immune cells after dosing, with normal measurements before the next treatment day. In his later account, Fauci also described extending the clinical investigations to conditions including polyarteritis nodosa and cerebral vasculitis. These historical studies linked patient observation, laboratory measurements, and evaluation of treatment toxicity within a collaborative research program; they did not establish a single regimen for every immune-mediated disease. (pubmed.ncbi.nlm.nih.gov)

HIV/AIDS Research and Clinical Investigation

Fauci redirected his laboratory toward HIV/AIDS research in 1981–1982, drawing on its existing work on human immune regulation. In a 2011 interview, he recalled that the June 5, 1981 report of Pneumocystis pneumonia in five previously healthy gay men, followed by further reports that summer, prompted his concern about a new disease. He admitted his first AIDS patient to the NIH Clinical Center in January 1982. The emerging research group included H. Clifford Lane, then a postdoctoral fellow, and critical-care physicians Joseph Parrillo and Henry Masur. Their initial approach combined clinical observation with laboratory characterization of the patients’ immune deficiencies, rather than attempts to isolate the still-unidentified causative virus. (fic.nih.gov)

A study published on August 25, 1983, by Lane, Masur, Lynn Edgar, Gail Whalen, Alain Rook, and Fauci demonstrated that AIDS involved abnormalities of B cells as well as T cells. The investigators compared 12 gay men with AIDS, five healthy gay men, and 12 heterosexual controls. Patients with AIDS had increased numbers of cells spontaneously secreting immunoglobulin, yet their B cells responded poorly to certain laboratory stimuli; helper-T-cell function was also deficient. These findings suggested polyclonal B-cell activation—activation across multiple B-cell populations—rather than a uniformly inactive immune system. The coexistence of excessive spontaneous antibody production and impaired responses helped explain why elevated immunoglobulin concentrations did not indicate effective immunity. (nejm.org)

Fauci and Lane also investigated whether transferring immune cells from healthy identical twins could restore immune function in affected siblings. These exploratory studies used genetically matched, or syngeneic, lymphocyte infusions and bone-marrow transplantation. A case report appeared in the New England Journal of Medicine in October 1984. In his 1993 oral history, Fauci described transient increases in CD4-positive cells followed by renewed deterioration. The procedures did not establish durable immune restoration; their limitations directed attention toward continuing viral replication and damage to the tissue environments needed to maintain immune cells. They were experimental attempts at immune reconstitution, not established AIDS therapies. (pubmed.ncbi.nlm.nih.gov)

Subsequent work examined infection within lymphoid tissues rather than relying only on blood measurements. In a March 25, 1993 Nature paper, Giuseppe Pantaleo, Cecilia Graziosi, Fauci, and collaborators compared viral burden and replication in blood and lymphoid organs from the same individuals. They found active infection in lymphoid tissue during the clinically latent stage, even when contemporary assays detected little viral activity in blood. Thus, an interval without overt clinical disease did not mean that HIV was biologically inactive. These tissue studies extended the laboratory’s investigation from abnormal immune-cell responses to the anatomical sites where infection persisted. (pubmed.ncbi.nlm.nih.gov)

This laboratory program formed one component of a wider collaborative effort, distinct from Fauci’s institute-wide administrative responsibilities. Lane connected laboratory findings with clinical investigations, while other groups studied cytokine regulation, cellular responses, and viral replication. The evidence supporting combination antiretroviral treatment came from separate multicenter trials: in 1997, Scott Hammer and the AIDS Clinical Trials Group 320 team reported that adding indinavir to two nucleoside analogues reduced progression to AIDS or death from 11% to 6% among 1,156 participants. Unlike the earlier cell-transfer experiments, this randomized trial demonstrated a clinical benefit from a drug combination directed against HIV replication. (history.nih.gov)

AIDS Activism and Participation in Research

During the late 1980s, AIDS advocates challenged both access to experimental medicines and the organization of federally supported research. Their demands included earlier availability of investigational drugs, less restrictive eligibility for clinical trials, greater attention to opportunistic infections, and participation in decisions about research priorities and protocols. ACT UP—the AIDS Coalition to Unleash Power—combined demonstrations with technical proposals. Its Treatment and Data Committee presented a proposal for expanded drug access to National Institute of Allergy and Infectious Diseases (NIAID) investigators and officials in April 1988. Committee member Jim Eigo argued for access by people excluded from trials who lacked reasonable treatment alternatives; Martin Delaney of Project Inform also pressed for greater patient autonomy in treatment decisions. These proposals helped establish the agenda for Fauci’s subsequent discussions with advocates. (ncbi.nlm.nih.gov)

One concrete result was Fauci’s endorsement of the “parallel track” concept in San Francisco in June 1989. It proposed making selected investigational drugs available to people unable to participate in conventional trials while controlled studies continued separately. The distinction was important: access to an unapproved medicine did not itself establish that the medicine was effective. Advocates developed and promoted the proposal; Fauci supported its adoption within the federal research establishment. Regulatory authority remained with the Food and Drug Administration (FDA), rather than NIAID. Subsequent negotiations over early access to didanosine, then generally called ddI, involved the FDA, NIH, the manufacturer Bristol-Myers, and activists. The ddI access program and development of a formal parallel-track policy proceeded through related but separate negotiations. (ncbi.nlm.nih.gov)

Fauci described the development of working relationships with activists in his June 29, 1993, NIH oral-history interview. He recalled inviting critics into discussions about their specific demands and reported that advocates had become members of advisory councils and regular participants in consultations. His account also identified a practical limitation of established research procedures: a scientifically rigorous protocol could still be so difficult for patients that they declined to enroll or obtained drugs outside formal research channels. He presented consultation as a way to understand these problems without relinquishing scientific standards. This retrospective account documents his stated approach, rather than establishing that cooperation displaced disagreement. (history.nih.gov)

Participation acquired an institutional structure within the AIDS Clinical Trials Group (ACTG). Biostatistician Susan Ellenberg organized an NIH–FDA conference on trial design in November 1989 and subsequently established a working group bringing together statisticians, investigators, activists, and people with AIDS. By July 1990, Fauci had announced that advocates would be represented across ACTG committees and activities. The Community Constituency Group became a formal ACTG committee; the National Research Council’s 1993 account recorded 24 members, two places on the ACTG Executive Committee, and representation on the core committees. Local trial units were also required to establish community advisory boards, providing channels for concerns about recruitment, adherence, and retention. These arrangements reflected contributions by advocates, statistical specialists, trial investigators, and institute staff, not simply a unilateral administrative decision. (nationalacademies.org)

The collaborations exposed a continuing division between responsiveness to immediate patient needs and responsibility for producing interpretable evidence. In the 1993 interview, Fauci distinguished community input into policy and research procedures from authority to override scientific validity. Advocates contributed knowledge of patients’ circumstances and challenged burdensome rules; investigators remained responsible for study design and interpretation, while regulators decided whether investigational products could be distributed or approved. Expanded access and participation in a controlled study therefore served different purposes: the former widened treatment options under uncertainty, whereas the latter sought reliable answers about safety and efficacy. (history.nih.gov)

Directorship of NIAID

Fauci directed the National Institute of Allergy and Infectious Diseases (NIAID) from November 1984 through December 31, 2022, a tenure of approximately 38 years. NIAID was a component of the National Institutes of Health (NIH), not a separate cabinet department, and Fauci’s directorship did not place him in charge of NIH as a whole. Its principal responsibility was biomedical research. This distinguished it from the Centers for Disease Control and Prevention, whose responsibilities included disease surveillance and prevention, and the Food and Drug Administration, which regulated medical products. These agencies collaborated, but their mandates and decision-making authorities remained separate. (nih.gov)

The portfolio Fauci oversaw combined basic investigations of pathogens and the immune system with applied research on prevention, diagnosis, and treatment. It encompassed established infectious diseases, including HIV/AIDS, respiratory and diarrheal infections, tuberculosis, and malaria, alongside newly emerging infections. NIAID also supported research on allergic and other immune-mediated conditions. Its remit therefore extended beyond epidemic response to the biological mechanisms underlying infection and abnormal immune activity, and to the development of diagnostics, medicines, and vaccines. (niaid.nih.gov)

Institute leadership operated through both internal laboratories and externally supported research. NIAID conducted laboratory studies and clinical investigations within its own research programs while supporting academic and other institutions through grants, contracts, and cooperative agreements. Its Office of the Director supplied scientific leadership, policy guidance, and administrative coordination; specialized divisions managed particular research portfolios and funding activities. This structure separated institute-wide priority setting from the conduct of individual experiments and clinical trials, and from the management and scientific review of external awards. (beta.nih.gov)

Fauci retained laboratory responsibilities alongside the directorship. Appointed chief of NIAID’s Laboratory of Immunoregulation in 1980, he continued in that position while leading the institute. Presidential advice constituted another, distinct responsibility: he served under and advised seven presidents, beginning with Ronald Reagan and ending with Joe Biden. His formal position as Biden’s chief medical adviser was separate from both his NIAID directorship and laboratory leadership. His August 22, 2022 departure announcement explicitly identified these as three positions that he would leave that December. (commdocs.house.gov)

His dealings with successive administrations and Congress concerned research priorities, funding, and preparedness against both naturally occurring infections and deliberate biological threats. The Lasker Foundation’s 2007 award account documented his advisory work with the White House and Department of Health and Human Services, including efforts to connect basic discoveries with the development of medical countermeasures. Congressional engagement also involved the regular appropriations process rather than only emergency hearings. NIAID’s account of its June 2021 advisory council meeting recorded that Fauci accompanied NIH director Francis Collins to House and Senate appropriations hearings on the president’s fiscal year 2022 NIH budget. At the same meeting, he discussed the administration’s proposed NIH increase of $9 billion, or 21 percent above the enacted fiscal year 2021 level—figures describing a budget proposal, not an appropriation already enacted by Congress. (laskerfoundation.org)

PEPFAR and International HIV/AIDS Programs

President George W. Bush announced the President’s Emergency Plan for AIDS Relief (PEPFAR) in his State of the Union address on January 28, 2003, proposing $15 billion over five years to expand the international response to HIV/AIDS. Its initial targets were to prevent 7 million new infections, provide antiretroviral therapy to 2 million people, and deliver care to 10 million people living with HIV and children orphaned by AIDS. The July 2003 White House implementation plan identified 14 focus countries in Africa and the Caribbean, including Uganda, South Africa, Haiti, and Guyana, while retaining assistance elsewhere and support for the Global Fund. These were prospective program targets, not reported achievements. (georgewbush-whitehouse.archives.gov)

Fauci helped develop the scientific and clinical rationale for this expansion. According to Harvey Fineberg’s presentation for Fauci’s 2007 Lasker Award, Bush asked Fauci, Health and Human Services Secretary Tommy Thompson, and others to visit Africa in 2002 to assess possible additional American assistance. Research in Uganda showing that a simplified nevirapine regimen could reduce mother-to-child HIV transmission supplied one concrete basis for action. After the visit, Thompson and White House deputy chief of staff Josh Bolten asked Fauci to develop a $500 million prevention proposal. Bush then requested a larger, feasible, and accountable initiative. Fauci worked with White House and other staff on the broader framework; the Lasker account identifies him as its principal scientific architect, rather than its sole designer or administrator. (laskerfoundation.org)

The design joined treatment, prevention, and care within a service-delivery network. The White House’s July 2003 plan envisaged central medical centers supporting satellite facilities and mobile units, alongside workforce training and improvements to healthcare infrastructure. Treatment access was also intended to encourage voluntary HIV testing, linking diagnosis to continuing care rather than offering testing without therapeutic follow-up. Prevention included counseling, measures against mother-to-child transmission, and behavioral interventions; care extended beyond medication to support for affected families and orphans. This operational model depended on strengthening local health systems, not merely purchasing medicines. (georgewbush-whitehouse.archives.gov)

PEPFAR was a multi-agency and international undertaking, separate from Fauci’s management of NIAID’s research portfolio. The State Department’s global AIDS coordinator oversaw assistance and interagency coordination; implementation involved agencies including USAID and the Centers for Disease Control and Prevention (CDC), working with host-country governments, clinicians, and nongovernmental and community organizations. NIAID’s distinct contribution lay in basic and clinical investigation, including research on treatments, prevention methods, and vaccines. It did not serve as the central administrator of PEPFAR’s overseas treatment network. (2021-2025.state.gov)

Dated program measurements show the scale reached during Fauci’s remaining years in federal service. In an analysis released on March 14, 2023, CDC reported that PEPFAR-supported antiretroviral treatment had expanded from approximately 66,500 recipients in 2004 to more than 20 million in 2022. Among treatment recipients with documented viral-load testing, the proportion with viral suppression rose from 80% in 2015 to 95% in 2022. The testing qualification matters: this was not a suppression estimate for every person receiving assistance. CDC also reported lower suppression in several groups, including children and adolescents. These figures describe the combined work of participating countries, implementing agencies, healthcare workers, and partner organizations, rather than an outcome attributable to Fauci individually. (cdc.gov)

Emerging Infections and Biodefense before COVID-19

Fauci’s work on emerging infections included explaining research priorities to federal policymakers. In Senate testimony on September 24, 2002, he described NIAID’s response to West Nile virus, first detected in the United States in 1999. This was a naturally emerging, mosquito-borne infection, maintained principally through transmission between mosquitoes and birds, rather than a deliberate biological release. He outlined research on viral ecology, diagnostic assays, antiviral compounds, and candidate vaccines. One experimental vaccine used a yellow-fever vaccine backbone carrying West Nile envelope genes; other approaches included DNA vaccines. His testimony also described how animal models and drug-screening systems could move candidates toward human testing, and how expanded biodefense research resources could support work on naturally emerging infections. (hsgac.senate.gov)

The 2001 anthrax letter attacks presented a different problem: intentional dissemination of a bacterial pathogen. The attacks produced 22 confirmed cases and five deaths, according to NIH’s June 2002 advisory-committee record. Fauci participated in developing the federal biodefense research strategy, linking basic investigation of dangerous organisms and host defenses to the development of medical countermeasures. NIAID’s 2002 planning process included a February expert panel and a research agenda addressing high-priority biological threats. The resulting program supported diagnostics, vaccines, therapeutics, animal models, and specialized laboratory facilities; its May 2002 funding notice identified more than $1 billion in proposed NIAID biodefense research funding for fiscal year 2003. These were research and development responsibilities, distinct from investigating the attacks or directing local emergency responses. (acd.od.nih.gov)

Pandemic influenza preparedness became another recurring subject of research leadership and presidential consultation. On October 7, 2005, Fauci joined Health and Human Services Secretary Michael Leavitt in briefing reporters after President George W. Bush met vaccine manufacturers about avian H5N1 influenza. The discussion addressed both immediate preparations and longer-term vaccine-production capacity, rather than assuming that the next pandemic would necessarily involve H5N1. During the 2009 H1N1 pandemic, Fauci announced NIAID-supported trials to establish vaccine dosage and scheduling. Initial protocols compared 15- and 30-microgram doses, assessed whether one or two injections were needed, and examined administration alongside seasonal influenza vaccine. These studies supplied clinical evidence for vaccination planning rather than constituting the vaccination campaign itself. (georgewbush-whitehouse.archives.gov)

During the 2014 West African Ebola emergency, Fauci’s responsibilities centered on scientific advice and accelerating candidate vaccines and treatments. In congressional testimony, he described NIAID’s collaboration with GlaxoSmithKline on a vaccine using chimpanzee adenovirus 3 to deliver genes encoding Ebola proteins. A phase 1 clinical trial began at the NIH Clinical Center on September 2, 2014, to assess safety and immune responses—not to establish protection against infection. NIAID also supported other vaccine platforms, preclinical testing, and therapeutic development. This research role was distinct from the field activities of affected countries, the World Health Organization, and CDC, including case identification, contact tracing, and infection control. (govinfo.gov)

During the Zika emergency, NIAID under Fauci advanced another experimental vaccine into human testing on August 3, 2016. The phase 1 study planned to enroll at least 80 healthy adults aged 18–35 at three United States sites. Developed by NIAID’s Vaccine Research Center, the candidate used a DNA plasmid encoding Zika proteins that could assemble into virus-like particles and elicit immune responses. Its design drew on earlier investigational West Nile vaccine work, illustrating the reuse of research platforms across emerging threats. The trial evaluated safety and immunogenicity; it did not establish clinical efficacy or replace operational measures to limit transmission. (irp.nih.gov)

COVID-19 Research and Presidential Advice

During the COVID-19 pandemic, Fauci combined leadership of the National Institute of Allergy and Infectious Diseases (NIAID) with presidential advice and public explanations of biomedical research. He was among the members of the White House Coronavirus Task Force announced by Donald Trump’s administration on January 29, 2020, which coordinated the federal response and briefed the president on developments. Under Joe Biden, Fauci became chief medical adviser at the beginning of the administration in January 2021 while continuing as NIAID director. His White House advisory position was separate from his responsibility for an institute conducting and supporting research on prevention, diagnosis, and treatment. (trumpwhitehouse.archives.gov)

NIAID’s collaboration with Moderna produced the investigational vaccine mRNA-1273. Its development drew on earlier studies of the coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Scientists at NIAID’s Vaccine Research Center and Moderna had already been developing a MERS vaccine targeting the spike protein, which enables coronavirus entry into human cells. When the genetic sequence of SARS-CoV-2 became available, they adapted their existing messenger RNA platform to encode a stabilized version of its spike protein. The approach directed recipients’ cells to produce the protein and thereby stimulate an immune response; it did not require administering the complete virus. These were collaborative laboratory and industrial contributions, distinct from Fauci’s institutional leadership. (nih.gov)

The first participant received mRNA-1273 on March 16, 2020, in a NIAID-funded phase 1 clinical trial at Kaiser Permanente Washington Health Research Institute in Seattle, led by Lisa A. Jackson. The initial open-label study was designed for 45 healthy adults aged 18–55, divided among three dose groups, with two injections approximately 28 days apart. Its immediate purposes were to assess safety and immune responses, not to establish protection against disease. Manufacturing for this stage received support from the Coalition for Epidemic Preparedness Innovations. (nih.gov)

Fauci’s public explanations distinguished rapid vaccine design from the longer process of clinical evaluation. During Trump’s March 3, 2020, visit to NIH, reported in the March 20 issue of the NIH Record, he contrasted the approximately 20 months required to begin a phase 1 SARS vaccine trial after identification of that pathogen in 2003 with the anticipated interval of less than three months for COVID-19. In early March presentations, he emphasized that phase 1 was only the beginning of larger trials and manufacturing scale-up needed to establish safety and effectiveness. These statements described expectations before efficacy results were available. (nihrecord.nih.gov)

Phase 3 testing began on July 27, 2020, with planned enrollment of approximately 30,000 adults. Moderna led the study as regulatory sponsor and supplied the vaccine; NIAID and the Biomedical Advanced Research and Development Authority provided funding. At its launch, Fauci explained that encouraging early safety and immune-response findings justified proceeding to a randomized, placebo-controlled trial to determine whether vaccination prevented COVID-19 and how long protection lasted. The subsequent FDA review reported 94.1% efficacy against symptomatic, confirmed COVID-19 beginning at least 14 days after the second dose in the primary analysis. On December 18, 2020, the Food and Drug Administration issued emergency use authorization for adults aged 18 and older. That regulatory decision belonged to the FDA, rather than to Fauci or NIAID, and was distinct from research funding, vaccine development, and trial conduct. (nih.gov)

Departure from Federal Service and Georgetown Appointment

On August 22, 2022, Fauci announced that he would leave three positions in December: director of the National Institute of Allergy and Infectious Diseases (NIAID), chief of its Laboratory of Immunoregulation, and chief medical adviser to President Joe Biden. The announcement encompassed his institute administration, laboratory leadership, and presidential advisory responsibilities, rather than merely a change in his directorship. His departure in December ended 54 years at the National Institutes of Health (NIH), including 38 years leading NIAID. In a June 2023 interview, he described the decision as an opportunity to undertake different work outside the federal government while remaining professionally active. (stagetestdomain3.nih.gov)

On June 26, 2023, Georgetown University announced his appointment as a Distinguished University Professor, effective July 1. His principal appointment was in the Division of Infectious Diseases within the School of Medicine’s Department of Medicine, with an additional appointment in the McCourt School of Public Policy. The university identified medical and graduate education and engagement with students as central responsibilities. These were academic appointments, distinct from the federal research-management and advisory offices he had relinquished. Georgetown described the University Professor rank as its highest professional honor for achievement in scholarship, teaching, and service. (georgetown.edu)

Fauci explained his choice of institution in terms of both location and academic scope. In the June 2023 interview, he said that he wanted to remain in Washington, D.C., join an academic community associated with a medical center, and work at the intersection of medicine and public policy. He explicitly distinguished these aims from continuing to operate a laboratory or run clinical trials. He presented experience-sharing and mentoring younger students—not only medical students—as the contribution he wished to emphasize. His stated priorities therefore extended beyond specialist instruction in infectious diseases to collaboration across professional and disciplinary boundaries. (georgetown.edu)

Documented activities included individual research mentoring and discussions with undergraduate and medical student groups. In October 2023, he met School of Health undergraduate Keerthana Ramanathan and agreed to assist with a survey for her honors thesis examining young adults’ hesitancy toward HPV vaccination. In spring 2024, he participated in a Pre-Med Society event concerning challenges in the U.S. health care system. He also met medical student Umayr Shaikh in December 2024 to discuss a possible article about communication in health care. On January 24, 2025, he joined Georgetown’s student Emergency Response Medical Service for a moderated discussion and questions. These activities were reported in the university’s February 7, 2025 account of his student engagement. (georgetown.edu)

His teaching also used public conversations to connect patient care, research, and government service. On January 15, 2025, School of Health dean Christopher King interviewed him in Georgetown’s Gaston Hall at an event titled “A Journey in Public Service.” Fauci described how exposure to research during his NIH fellowship had changed his original plan to practice medicine in New York City: findings generated through research, he explained, could influence care beyond an individual patient by informing other health professionals’ work. The discussion provided students with his retrospective account of the relationship between clinical practice and public health responsibilities. (health.georgetown.edu)

Publications and Major Honors

Fauci’s scientific publications include original investigations with clinical and laboratory collaborators, as well as reviews synthesizing research on infectious diseases. An early example is “Effect of Cyclophosphamide upon the Immune Response in Wegener’s Granulomatosis,” published in the New England Journal of Medicine on December 30, 1971, with Fauci, Sheldon M. Wolff, and J. S. Johnson as its three authors. His subsequent HIV/AIDS bibliography includes “Abnormalities of B-Cell Activation and Immunoregulation in Patients with the Acquired Immunodeficiency Syndrome,” published in the same journal on August 25, 1983. That original research article lists H. Clifford Lane as first author and Fauci as the last of six authors, documenting the collaborative authorship of the laboratory’s AIDS investigations. (pubmed.ncbi.nlm.nih.gov)

A different category is represented by “Emerging Pandemic Diseases: How We Got to COVID-19,” coauthored with David M. Morens and published in Cell in September 2020. This review brought together historical, ecological, and biomedical literature on disease emergence rather than reporting a new patient cohort or clinical trial. Its place in Fauci’s bibliography therefore differs from that of the earlier experimental papers: it is a jointly authored synthesis connecting infectious-disease research with the broader history of epidemics. (pubmed.ncbi.nlm.nih.gov)

Fauci also served on the collective editorial team of Harrison’s Principles of Internal Medicine. The 21st edition, published in 2022, identifies six editors: Joseph Loscalzo, Dennis L. Kasper, Dan L. Longo, Fauci, Stephen L. Hauser, and J. Larry Jameson. Its editorial page explicitly states that Fauci’s work as editor and author was undertaken outside his federal employment and did not necessarily represent United States government views. The 22nd edition likewise lists him among its editors, alongside the other five and Steven M. Holland and Carol A. Langford. These credits identify participation in a shared editorial enterprise, not sole authorship of the textbook. (info.mheducation.com)

His memoir, On Call: A Doctor’s Journey in Public Service, appeared in June 2024. It covers his upbringing, medical career, and experiences advising presidents during successive health emergencies. In Georgetown University’s June 18 account of the publication, Fauci said that he had first envisaged the book during Bill Clinton’s presidency and had subsequently accumulated notes about his experiences. The book is thus a retrospective personal account and a source for Fauci’s recollections and stated motivations, rather than an independently authored history of the institutions and events it describes. (georgetown.edu)

The 2007 Mary Woodard Lasker Award for Public Service was announced on September 16, with its presentation ceremony scheduled for September 28 in New York City. The Lasker Foundation’s citation recognized Fauci’s role in developing two government programs addressing AIDS and biodefense; its accompanying account identified the President’s Emergency Plan for AIDS Relief and federal preparedness against biological threats. The award recognized public service rather than a single experimental discovery. (laskerfoundation.org)

On June 19, 2008, President George W. Bush presented Fauci with the Presidential Medal of Freedom at the White House. The formal citation recognized his work as a physician, researcher, author, and public servant, specifically mentioning advances in understanding and treating HIV/AIDS. Bush’s accompanying remarks also identified Fauci’s contribution to the Emergency Plan for AIDS Relief. These were the awarding administration’s stated grounds for the honor. (georgewbush-whitehouse.archives.gov)

References

1. COVID Crusader: Anthony Fauci, M.D., ’62magazine.holycross.edu
2. Dr. Fauci at Holy Crosslibguides.holycross.edu
3. Fauci Reflects on How Jesuit Values Have Shaped His Careergeorgetown.edu
4. Introduction of Anthony S. Fauci, MD: 2007 Association of American Physicians George M. Kober Medalpmc.ncbi.nlm.nih.gov
5. Notable Alumnimedicine.weill.cornell.edu
6. American Masters: Tony – A Year in the Life of Dr. Anthony Faucipbs.org
7. Effect of cyclophosphamide upon the immune response in Wegener's granulomatosispubmed.ncbi.nlm.nih.gov
8. Wegener's granulomatosis: studies in eighteen patients and a review of the literaturepubmed.ncbi.nlm.nih.gov
9. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 yearspubmed.ncbi.nlm.nih.gov
10. The effect of in vivo hydrocortisone on subpopulations of human lymphocytespubmed.ncbi.nlm.nih.gov
11. The effect of cyclophosphamide on leukocyte kinetics and susceptibility to infection in patients with Wegener's granulomatosispubmed.ncbi.nlm.nih.gov
12. Alternate-day prednisone. Leukocyte kinetics and susceptibility to infectionspubmed.ncbi.nlm.nih.gov
13. Alternate-day prednisone therapy and human lymphocyte subpopulationspubmed.ncbi.nlm.nih.gov
14. Q and A with NIAID Director Dr. Anthony S. Faucific.nih.gov
15. Partial immune reconstitution in a patient with the acquired immunodeficiency syndromepubmed.ncbi.nlm.nih.gov
16. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of diseasepubmed.ncbi.nlm.nih.gov
17. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Teampubmed.ncbi.nlm.nih.gov
18. Unproven AIDS Therapies: The Food and Drug Administration and ddIncbi.nlm.nih.gov
19. Historical Perspective — Expanding Access to Investigational Therapies for HIV Infection and AIDSncbi.nlm.nih.gov
20. The Social Impact of AIDS in the United States — Clinical Research and Drug Regulationnationalacademies.org
21. Report on NIH Collaborations with Other HHS Agencies for Fiscal Year 2016dpcpsi.nih.gov
22. Anthony S. Fauci, M.D.niaid.nih.gov
23. Advancements in AIDS relief and biodefenselaskerfoundation.org
24. Organization | NIAIDbeta.nih.gov
25. Homeland Security: The Federal and Regional Responsecommdocs.house.gov
26. Recap of June’s Advisory Council Meetingniaid.nih.gov
27. Fact Sheet: The President’s Emergency Plan for AIDS Reliefgeorgewbush-whitehouse.archives.gov
28. About Us – PEPFAR2021-2025.state.gov
29. HIV Research Activitieshiv.gov
30. HIV Prevention Activitieshiv.gov
31. U.S.-Led Global Effort Dramatically Increases Number of People Receiving Lifesaving HIV Treatment in Less than Two Decadescdc.gov
32. The State of West Nile Virus Research at the National Institutes of Healthhsgac.senate.gov
33. NIAID Biodefense Research Agenda for CDC Category A Agentsniaid.nih.gov
34. Biodefense and Emerging Infectious Diseases Research Opportunitiesgrants.nih.gov
35. President Meets with Vaccine Industry Representatives to Discuss Avian Flugeorgewbush-whitehouse.archives.gov
36. Fall flu outbreak of concern to NIH, Fogarty expertsfic.nih.gov
37. Ebola in West Africa: A Global Challenge and Public Health Threatgovinfo.gov
38. CDC Telebriefing on the Update on Ebola outbreak in West Africaarchive.cdc.gov
39. NIH begins testing investigational Zika vaccine in humansirp.nih.gov
40. Statement from the Press Secretary Regarding the President’s Coronavirus Task Forcetrumpwhitehouse.archives.gov
41. Biden team elevates science, global engagementfic.nih.gov
42. Moderna COVID-19 Vaccine EUA FDA review memorandumfda.gov
43. FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccinecontent.govdelivery.com
44. Dr. Anthony S. Fauci To Join Georgetown Faculty as Distinguished University Professorgeorgetown.edu
45. 5 Questions for Dr. Fauci on Why He Decided To Join Georgetowngeorgetown.edu
46. Dr. Fauci Makes the Rounds with Students on Campusgeorgetown.edu
47. Through Sharing His ‘Journey in Public Service,’ Fauci Encourages Students to Pursue Their Passionshealth.georgetown.edu
48. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndromepubmed.ncbi.nlm.nih.gov
49. Emerging Pandemic Diseases: How We Got to COVID-19pubmed.ncbi.nlm.nih.gov
50. Emerging Pandemic Diseases: How We Got to COVID-19pmc.ncbi.nlm.nih.gov
51. McGraw Hill Spring 2022 Front Listinfo.mheducation.com
52. Dr. Fauci Publishes Memoir Chronicling Career To Inspire Next Generation of Public Servantsgeorgetown.edu
53. 2007 Lasker Awardslaskerfoundation.org
54. President Bush Honors Presidential Medal of Freedom Recipientsgeorgewbush-whitehouse.archives.gov